Development

Hemanth Kaligotla is a bioprocessing and commercial business development leader.

Uwe Gottschalk is operating partner at Keensight Capital.

Articles

Innovations in downstream processing accelerate development, enhance efficiency, and promote sustainability.

Innovations in Downstream Processing

Feliza Mirasol is the science editor for 

Scale-up strategies for cell culture will require a deep understanding of overall bioprocess workflows.

A Look into Biologic Scale-Up Strategies

Evan Zynda, PhD, is senior scientist at Thermo Fisher Scientific.

Scaling cell therapy production workflows requires the establishment of closed, automated steps.

Addressing Cell Therapy Challenges Through a Modular, Closed, and Automated Manufacturing System

Chris Spivey is the editorial director of 

Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.

How mRNA will Shift Pharma Commercial Models with Jane True, Pfizer

Improvement in viral vector yield has become integral to new cell and gene therapy product development.

Optimizing Vectors to Standardize Success

Scott Ripley is the general manager, nucleic acid, for Cytiva.

Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.

Accelerating the Development of mRNA Therapeutics

Grant Playter is the Assistant Editor for 

Scaling up chromatography resins requires a thorough understanding of their intended use.

Approaches to Scaling Up Chromatography Processes

Stéphane Varray, PhD, is senior director, head of Commercial Development, Microbial Business Unit, at Lonza.

Successful scale-up and BLA filings for products manufactured by microbial biomanufacturing require strategic planning.

Outlining Successful Steps for Scale-Up and BLA Filings

The growing demand for antibody and other bio-therapeutics will require long-term scale-up solutions.

Large-Scale Single-Use Bioreactors Can Maximize Long-Term Scale Up

Takeda has exercised an option to co-develop and co-commercialize an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin.